Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease

REFERENCES

• Chaplin DD. Overview of the immune response. J Allergy Clin Immunol 2010;125(2 Suppl 2):S3–23.
   PubMed Web of Science ®Google Scholar
• Tanasescu R, Constantinescu CS. Cannabinoids and the immune system: an overview. Immunobiology 2010;215(8):588–597.
   PubMed Web of Science ®Google Scholar
• Gaoni Y, Mechoulam R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. J Am Chem Soc 1964;86(8):1646–1647.
   Web of Science ®Google Scholar
• Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346(6284):561–564.
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1992;365:61–65.
   Web of Science ®Google Scholar
• Rossi S, Bernardi G, Centonze D. The cannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and amyotrophic lateral sclerosis. Exp Neurol 2010;224:92–102.
   PubMed Web of Science ®Google Scholar
• Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946–1949.
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995;50(1):83–90.
   PubMed Web of Science ®Google Scholar
• Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995;215(1):89–97.
   PubMed Web of Science ®Google Scholar
• Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P. Endocannabinoids and immune regulation. Pharmacol Res 2009;60:85–92.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, De Petrocellis L, Bisogno T. The biosynthesis, fate and pharmacological properties of endocannabinoids. Handbook Exp Pharmacol 2005;168:147–185.
   PubMedGoogle Scholar
• Liu J, Wang L, Harvey-White J, et al. A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A 2006;103(36):13345–13350.
   PubMed Web of Science ®Google Scholar
• Bisogno T. Endogenous cannabinoids: structure and metabolism. J Neuroendocrinol 2008;20(Suppl 1):1–9.
   PubMed Web of Science ®Google Scholar
• Fowler CJ. The pharmacology of the cannabinoid system–a question of efficacy and selectivity. Mol Neurobiol 2007;36(1):15–25.
   PubMed Web of Science ®Google Scholar
• Cravatt BF, Lichtman AH. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol. 2004;61(1):149–160.
   PubMedGoogle Scholar
• Ueda N. Endocannabinoid hydrolases. Prostaglandins Other Lipid Mediat 2002;68–69:521–534.
   PubMed Web of Science ®Google Scholar
• Dinh TP, Freund TF, Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 2002;121(1–2):149–158.
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Holt S, Nilsson O, et al. The endocannabinoid signaling system: pharmacological and therapeutic aspects. Pharmacol Biochem Behav 2005;81(2):248–262.
   PubMed Web of Science ®Google Scholar
• Porter AC, Sauer JM, Knierman MD, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002;301(3):1020–1024.
   PubMed Web of Science ®Google Scholar
• Toth A, Blumberg PM, Boczan J. Anandamide and the vanilloid receptor (TRPV1). Vitam Horm 2009;81:389–419.
   PubMed Web of Science ®Google Scholar
• Ryberg E, Larsson N, Sjogren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007;152(7):1092–1101.
   PubMed Web of Science ®Google Scholar
• Cabral GA, Raborn ES, Griffin L, et al. CB2 receptors in the brain: role in central immune function. Br J Pharmacol 2008;153(2):240–251.
   PubMed Web of Science ®Google Scholar
• Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998;394(6690):277–281.
   PubMed Web of Science ®Google Scholar
• Facci L, Dal Toso R, Romanello S, et al. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 1995;92(8):3376–3380.
   PubMed Web of Science ®Google Scholar
• Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999;400(6743):452–457.
   PubMed Web of Science ®Google Scholar
• Mezey E, Toth ZE, Cortright DN, et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A 2000;97(7):3655–3660.
   PubMed Web of Science ®Google Scholar
• Saunders CI, Fassett RG, Geraghty DP. Up-regulation of TRPV1 in mononuclear cells of end-stage kidney disease patients increases susceptibility to N-arachidonoyl-dopamine (NADA)-induced cell death. Biochim Biophys Acta 2009;1792(10):1019–1026.
   PubMed Web of Science ®Google Scholar
• Sharir H, Abood ME. Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther 2010;126(3):301–313.
   PubMed Web of Science ®Google Scholar
• Oka S, Nakajima K, Yamashita A, et al. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 2007;362(4):928–934.
   PubMed Web of Science ®Google Scholar
• Moldrich G, Wenger T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides 2000;21(11):1735–1742.
   PubMed Web of Science ®Google Scholar
• Parolaro D. Presence and functional regulation of cannabinoid receptors in immune cells. Life Sci 1999;65:637–644.
   PubMed Web of Science ®Google Scholar
• Onaivi ES, Ishiguro H, Gong JP, et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 2006;1074:514–536.
   PubMed Web of Science ®Google Scholar
• Barnett-Norris J, Hurst DP, Lynch DL, et al. Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor. J Med Chem 2002;45(17):3649–3659.
   PubMed Web of Science ®Google Scholar
• Song ZH, Bonner TI. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212–2. Mol Pharmacol 1996;49(5):891–896.
   PubMed Web of Science ®Google Scholar
• Bouaboula M, Dussossoy D, Casellas P. Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. J Biol Chem 1999;274(29):20397–20405.
   PubMed Web of Science ®Google Scholar
• Song ZH, Slowey CA, Hurst DP, Reggio PH. The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212–2 for CB(2). Mol Pharmacol 1999;56(4):834–840.
   PubMed Web of Science ®Google Scholar
• Feng W, Song ZH. Effects of D3.49A, R3.50A, and A6.34E mutations on ligand binding and activation of the cannabinoid-2 (CB2) receptor. Biochem Pharmacol 2003;65(7):1077–1085.
   PubMed Web of Science ®Google Scholar
• McAllister SD, Rizvi G, Anavi-Goffer S, et al. An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem 2003;46(24):5139–5152.
   PubMed Web of Science ®Google Scholar
• Croxford JL, Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroimmunol 2005;166(1–2):3–18.
   PubMed Web of Science ®Google Scholar
• Daigle TL, Kwok ML, Mackie K. Regulation of CB1 cannabinoid receptor internalization by a promiscuous phosphorylation-dependent mechanism. J Neurochem 2008;106(1):70–82.
   PubMed Web of Science ®Google Scholar
• Ribeiro A, Ferraz-de-Paula V, Pinheiro ML, et al. Anandamide prior to sensitization increases cell-mediated immunity in mice. Int Immunopharmacol 2010;10(4):431–439.
   PubMed Web of Science ®Google Scholar
• Borner C, Hollt V, Kraus J. Activation of human T cells induces upregulation of cannabinoid receptor type 1 transcription. Neuroimmunomodulation 2007;14(6):281–286.
   PubMed Web of Science ®Google Scholar
• Lee M, Yang KH, Kaminski NE. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J Pharmacol Exp Ther 1995;275(2):529–536.
   PubMed Web of Science ®Google Scholar
• Rockwell CE, Raman P, Kaplan BL, Kaminski NE. A COX-2 metabolite of the endogenous cannabinoid, 2-arachidonyl glycerol, mediates suppression of IL-2 secretion in activated Jurkat T cells. Biochem Pharmacol 2008;76(3):353–361.
   PubMed Web of Science ®Google Scholar
• Ouyang Y, Hwang SG, Han SH, Kaminski NE. Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells. Mol Pharmacol 1998;53(4):676–683.
   PubMed Web of Science ®Google Scholar
• Schwarz H, Blanco FJ, Lotz M. Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. J Neuroimmunol 1994;55(1):107–115.
   PubMed Web of Science ®Google Scholar
• Howlett AC, Mukhopadhyay S. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem Phys Lipids 2000;108(1–2):53–70.
   PubMed Web of Science ®Google Scholar
• Galve-Roperh I, Sanchez C, Cortes ML, et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000;6(3):313–319.
   PubMed Web of Science ®Google Scholar
• Jackson AR, Hegde VL, Nagarkatti PS, Nagarkatti M. Characterization of endocannabinoid-mediated induction of myeloid-derived suppressor cells involving mast cells and MCP-1. J Leukoc Biol 2014;95(4):609–619.
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004;3(9):771–784.
   PubMed Web of Science ®Google Scholar
• Jean-Gilles L, Feng S, Tench CR, et al. Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci 2009;287(1–2):212–215.
   PubMed Web of Science ®Google Scholar
• Loria F, Petrosino S, Mestre L, et al. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur J Neurosci 2008;28(4):633–641.
   PubMed Web of Science ®Google Scholar
• Ortega-Gutierrez S, Molina-Holgado E, Arevalo-Martin A, et al. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. FASEB J: official publication of the Federation of American Societies for Experimental Biology. 2005;19(10):1338–1340.
   PubMed Web of Science ®Google Scholar
• Zajicek JP, Apostu VI. Role of cannabinoids in multiple sclerosis. CNS Drugs 2011;25(3):187–201.
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet 2002;359(9313):1221–1231.
   PubMed Web of Science ®Google Scholar
• Rossi S, Bernardi G, Centonze D. The endocannabinoid system in the inflammatory and neurodegenerative processes of multiple sclerosis and of amyotrophic lateral sclerosis. Exp Neurol 2010;224(1):92–102.
   PubMed Web of Science ®Google Scholar
• Klegeris A, Bissonnette CJ, McGeer PL. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol 2003;139(4):775–786.
   PubMed Web of Science ®Google Scholar
• Molina-Holgado F, Lledo A, Guaza C. Anandamide suppresses nitric oxide and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. Neuroreport 1997;8(8):1929–1933.
   PubMed Web of Science ®Google Scholar
• Borner C, Hollt V, Sebald W, Kraus J. Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids. J Leukocyte Biol 2007;81(1):336–343.
   PubMed Web of Science ®Google Scholar
• Marsicano G, Goodenough S, Monory K, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003;302(5642):84–88.
   PubMed Web of Science ®Google Scholar
• Felder CC, Joyce KE, Briley EM, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995;48(3):443–450.
   PubMed Web of Science ®Google Scholar
• Ryan D, Drysdale AJ, Lafourcade C, et al. Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels. J Neurosci. 2009;29(7):2053–2063.
   PubMed Web of Science ®Google Scholar
• Eljaschewitsch E, Witting A, Mawrin C, et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006;49(1):67–79.
   PubMed Web of Science ®Google Scholar
• Centonze D, Bari M, Rossi S, et al. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain: A Journal of Neurology 2007;130(Pt 10):2543–2553.
   PubMed Web of Science ®Google Scholar
• Witting A, Chen L, Cudaback E, et al. Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. Proc Natl Acad Sci U S A 2006;103(16):6362–6367.
   PubMed Web of Science ®Google Scholar
• Witting A, Walter L, Wacker J, et al. P2 × 7 receptors control 2-arachidonoylglycerol production by microglial cells. Proc Natl Acad Sci U S A 2004;101(9):3214–3219.
   PubMed Web of Science ®Google Scholar
• Lourbopoulos A, Grigoriadis N, Lagoudaki R, et al. Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. Brain Res 2011;1390:126–141.
   PubMed Web of Science ®Google Scholar
• Correa F, Hernangomez-Herrero M, Mestre L, et al. The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells. Brain Behav Immun 2011;25(4):736–749.
   PubMed Web of Science ®Google Scholar
• Loria F, Petrosino S, Hernangomez M, et al. An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol Dis 2010;37(1):166–176.
   PubMed Web of Science ®Google Scholar
• Rossi S, Furlan R, De Chiara V, et al. Cannabinoid CB1 receptors regulate neuronal TNF-alpha effects in experimental autoimmune encephalomyelitis. Brain Behav Immun 2011;25(6):1242–1248.
   PubMed Web of Science ®Google Scholar
• Maccarrone M, Valensise H, Bari M, et al. Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility. J Immunol 2001;166(12):7183–7189.
   PubMed Web of Science ®Google Scholar
• Di Filippo M, Pini LA, Pelliccioli GP, et al. Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. J Neurol, Neurosurg Psychiatry 2008;79(11):1224–1229.
   PubMed Web of Science ®Google Scholar
• Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991;88(4):1370–1378.
   PubMed Web of Science ®Google Scholar
• Volkmann M, Martin L, Baurle A, et al. Soluble liver antigen: isolation of a 35-kd recombinant protein (SLA-p35) specifically recognizing sera from patients with autoimmune hepatitis. Hepatology. 2001;33(3):591–596.
   PubMed Web of Science ®Google Scholar
• Kita H, Mackay IR, Van De Water J, Gershwin ME. The lymphoid liver: considerations on pathways to autoimmune injury. Gastroenterology 2001;120(6):1485–1501.
   PubMed Web of Science ®Google Scholar
• Strassburg CP. Autoimmune hepatitis. Best Pract Res Clin Gastroenterol 2010;24(5):667–682.
   PubMed Web of Science ®Google Scholar
• Kirk AP, Jain S, Pocock S, et al. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut 1980;21(1):78–83.
   PubMed Web of Science ®Google Scholar
• Xu X, Liu Y, Huang S, et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 2006;171(1):31–38.
   PubMed Web of Science ®Google Scholar
• Batkai S, Jarai Z, Wagner JA, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001;7(7):827–832.
   PubMed Web of Science ®Google Scholar
• Ros J, Claria J, To-Figueras J, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002;122(1):85–93.
   PubMed Web of Science ®Google Scholar
• Magen I, Avraham Y, Berry E, Mechoulam R. Endocannabinoids in liver disease and hepatic encephalopathy. Curr Pharm Des 2008;14(23):2362–2369.
   PubMed Web of Science ®Google Scholar
• Batkai S, Osei-Hyiaman D, Pan H, et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J 2007;21(8):1788–1800.
   PubMed Web of Science ®Google Scholar
• Hegde VL, Hegde S, Cravatt BF, et al. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells. Mol Pharmacol 2008;74(1):20–33.
   PubMed Web of Science ®Google Scholar
• Siegmund SV, Seki E, Osawa Y, et al. Fatty acid amide hydrolase determines anandamide-induced cell death in the liver. J Biol Chem 2006;281(15):10431–10438.
   PubMed Web of Science ®Google Scholar
• Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998;102(3):538–549.
   PubMed Web of Science ®Google Scholar
• Siegmund SV, Qian T, de Minicis S, et al. The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J: official publication of the Federation of American Societies for Experimental Biology 2007;21(11):2798–2806.
   PubMed Web of Science ®Google Scholar
• Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006;12(6):671–676.
   PubMed Web of Science ®Google Scholar
• Akhmetshina A, Dees C, Busch N, et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 2009;60(4):1129–1136.
   PubMed Web of Science ®Google Scholar
• Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358(9285):903–911.
   PubMed Web of Science ®Google Scholar
• McQueen FM, Stewart N, Crabbe J, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 1998;57(6):350–356.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996;14:397–440.
   PubMed Web of Science ®Google Scholar
• Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992;89(20):9784–9788.
   PubMed Web of Science ®Google Scholar
• Joosten LA, Helsen MM, van de Loo FA, van den Berg WB. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum 1996;39(5):797–809.
   PubMed Web of Science ®Google Scholar
• Naidu PS, Kinsey SG, Guo TL, et al. Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. J Pharmacol Exp Ther 2010;334(1):182–190.
   PubMed Web of Science ®Google Scholar
• Compton DR, Gold LH, Ward SJ, et al. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 1992;263(3):1118–1126.
   PubMed Web of Science ®Google Scholar
• Eros G, Ibrahim S, Siebert N, et al. Oral phosphatidylcholine pretreatment alleviates the signs of experimental rheumatoid arthritis. Arthritis Res Ther 2009;11(2):R43.
   PubMed Web of Science ®Google Scholar
• Lowin T, Zhu W, Dettmer-Wilde K, Straub RH. Cortisol-mediated adhesion of synovial fibroblasts is dependent on the degradation of anandamide and activation of the endocannabinoid system. Arthritis Rheum 2012;64(12):3867–3876.
   PubMed Web of Science ®Google Scholar
• Richardson D, Pearson RG, Kurian N, et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 2008;10(2):R43.
   PubMed Web of Science ®Google Scholar